No business profile yet.
Size Steminent Biotherapeutics (7729.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $668M, the 341st largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$290.00 on 18 Nov 2026.
Performance Over six months the shares gained 291.9%, against -17.6% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 2nd highest of 19 in its peer set.
Capital Return on invested capital runs 98.2 points below its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$0 | NT$0 | NT$0 | NT$941,000 | NT$636,000 |
| Revenue growth | — | — | -100% | +48% | — |
| Gross profit | -NT$31.8M | -NT$30.9M | -NT$16.4M | -NT$12.7M | -NT$18.3M |
| EBITDA | -NT$177M | -NT$143M | -NT$146M | -NT$119M | -NT$88.8M |
| Net income | -NT$204M | -NT$174M | -NT$159M | -NT$129M | -NT$85.5M |
| Free cash flow | -NT$179M | -NT$140M | -NT$227M | -NT$142M | -NT$71.5M |
| Capital expenditure | NT$5.12M | NT$7.76M | NT$88.4M | NT$27.7M | NT$2.51M |
| Total debt | NT$65.2M | NT$77.4M | NT$63.8M | NT$75.4M | NT$55.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 7729.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +50.3% | -7.3% | highest of 21 |
| 6-month return | +291.9% | -17.6% | 2nd highest of 19 |
| Distance from 52-week high | -3.6% | -44.8% | highest of 21 |
| ROIC minus cost of capital | -98.2 pp | -11.3 pp | lowest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 6.7× | n/a | n/a |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | 2.6× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | 11.4× | 40.3% | +21.5% |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | 38.1× | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | 14.7× | 44.8% | +14.7% |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | 105.4× | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 2.8× | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 4.4× | n/a | n/a |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | 220.7× | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | 2.6× | -8.9% | -1.3% |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 3.4× | 17.3% | +11.8% |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | 10.8× | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | 6.9× | -13.5% | -10.9% |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | 48.5× | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 1.9× | n/a | n/a |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |